Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,546 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,539 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05756907 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 40 | Sonnet BioTherapeuticsINDUSTRY | 2 | Feb 3, 2026 | clinicaltrials |
| NCT04856189 | Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma | terminated | Phase 1 / Phase 2 | 4 | Mamta ParikhOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06457997 | A Study of PHN-010 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 26 | Pheon TherapeuticsINDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | TakedaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05357027 | HPV16 E6 TCR T Cells for Cervical Carcinoma | terminated | Phase 1 / Phase 2 | 5 | TCRCure Biopharma Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT02948426 | Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | terminated | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | terminated | Phase 1 | 78 | Fusion Pharmaceuticals Inc.INDUSTRY | 3 | Jan 7, 2026 | clinicaltrials |
| NCT03260504 | Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer | terminated | Phase 1 | 6 | University of WashingtonOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | terminated | Phase 1 | 50 | Blueprint Medicines CorporationINDUSTRY | 3 | Nov 28, 2025 | clinicaltrials |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies | terminated | Phase 1 | 17 | Bolt Biotherapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05037500 | Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer | terminated | Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05119335 | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 120 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | terminated | Phase 1 / Phase 2 | 8 | Alaunos TherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05617040 | Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer | terminated | Phase 1 / Phase 2 | 22 | Barinthus BiotherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 82 | Nuvation Bio Inc.INDUSTRY | 2 | Nov 6, 2025 | clinicaltrials |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 31 | HiFiBiO TherapeuticsINDUSTRY | 2 | Oct 22, 2025 | clinicaltrials |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | terminated | Phase 1 | 25 | Incyte CorporationINDUSTRY | 2 | Oct 21, 2025 | clinicaltrials |
| NCT03792841 | Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC | terminated | Phase 1 | 212 | AmgenINDUSTRY | 10 | Oct 16, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT05276492 | Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. | terminated | Phase 1 | 50 | University of ChicagoOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 23 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05200364 | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer | terminated | Phase 1 | 58 | Sutro Biopharma, Inc.INDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | terminated | Phase 1 | 9 | PfizerINDUSTRY | 3 | Sep 17, 2025 | clinicaltrials |
| NCT05733351 | Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer | terminated | Phase 1 | 4 | Emory UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05708924 | MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | terminated | Phase 1 | 1 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT04611126 | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer | terminated | Phase 1 / Phase 2 | 6 | Inge Marie SvaneOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05369000 | Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer | terminated | Phase 1 | 96 | Lava TherapeuticsINDUSTRY | 3 | Aug 1, 2025 | clinicaltrials |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 11 | Numab Therapeutics AGINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | terminated | Phase 1 | 5 | Craig L Slingluff, JrOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | HutchmedINDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | terminated | Phase 1 | 57 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03815942 | VAccination in Early and ADvanced Prostate caNCEr(ADVANCE) | terminated | Phase 1 / Phase 2 | 23 | University of OxfordOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT04740034 | A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma | terminated | Phase 1 | 42 | AmgenINDUSTRY | 1 | Jun 17, 2025 | clinicaltrials |
| NCT04019288 | AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT03712371 | Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 12 | Medical University of South CarolinaOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | terminated | Phase 1 | 221 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03277482 | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | terminated | Phase 1 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT03294694 | Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer | terminated | Phase 1 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | terminated | Phase 1 | 85 | PfizerINDUSTRY | 5 | May 28, 2025 | clinicaltrials |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | Numab Therapeutics AGINDUSTRY | 3 | May 23, 2025 | clinicaltrials |
| NCT04927663 | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression | terminated | Phase 1 | 2 | Rahul AggarwalOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT03300505 | ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 9 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05242822 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations | terminated | Phase 1 | 54 | Kinnate BiopharmaINDUSTRY | 6 | May 7, 2025 | clinicaltrials |
| NCT01341288 | Robotic Seed Implantation for Prostate Cancer Brachytherapy(EUCLIDIAN) | terminated | Phase 1 | 2 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | terminated | Phase 1 | 27 | Turnstone Biologics, Corp.INDUSTRY | 3 | Apr 23, 2025 | clinicaltrials |
| NCT04514692 | Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging | terminated | Phase 1 / Phase 2 | 7 | Stanford UniversityOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT04875806 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 40 | NextCure, Inc.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04556617 | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 19 | Opna Bio LLCINDUSTRY | 2 | Apr 8, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Feb 3, 2026source: clinicaltrials